Rapid Weight Loss from Semaglutide Linked to Euthyroid Sick Syndrome
Background
Euthyroid sick syndrome (ESS), also known as non-thyroidal illness syndrome, is a condition characterized by abnormal thyroid function tests—most notably a low triiodothyronine (T3) level—occurring despite the thyroid gland itself being healthy. It typically arises during severe illness, starvation, or other catabolic states. While semaglutide is highly effective for weight management, the potential for rapid weight loss induced by this medication to precipitate ESS in otherwise healthy individuals has not been widely documented.
Study Design
Why It Matters
This case highlights a crucial, though likely rare, adverse event associated with rapid weight loss induced by semaglutide, a widely used GLP-1 receptor agonist. Clinicians prescribing semaglutide should be aware of the potential for ESS to develop in patients experiencing significant and rapid weight loss, and consider it in the differential diagnosis for new-onset fatigue or cold intolerance. Recognizing this physiological adaptation, rather than intrinsic thyroid disease, is vital to avoid unnecessary thyroid hormone replacement and ensure appropriate patient counseling. Further research, potentially through larger observational studies or clinical trials, is needed to determine the prevalence and specific risk factors for ESS in this growing patient population.